CTLA4 and triple-negative breast carcinoma: Previously, we have reported that combination immunotherapy of MUC1 mRNA nanovaccine and CTLA-4 blockade can effectively inhibit growth of triple negative breast cancer and significantly increase the number of tumor-infiltrating CD8+T cells compared to the vaccine or anti-CTLA-4 monoclonal antibody alone [19].